1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Amgen Acquires BioVex Group

M&A Deal Summary

Amgen Acquires BioVex Group

On January 24, 2011, Amgen acquired life science company BioVex Group for 1.0B USD

Acquisition Highlights
  • This is Amgen’s 8th transaction in the Life Science sector.
  • This is Amgen’s 10th largest (disclosed) transaction.
  • This is Amgen’s 8th transaction in the United States.
  • This is Amgen’s 3rd transaction in Massachusetts.

M&A Deal Summary
Date 2011-01-24
Target BioVex Group
Sector Life Science
Buyer(s) Amgen
Deal Type Add-on Acquisition
Deal Value 1.0B USD

Target

BioVex Group

Woburn, Massachusetts, United States
BioVex Group, Inc. is a biotechnology company based in Woburn, Mass., with additional operations in Abingdon, UK. BioVex produces OncoVEX(GM-CSF), a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer.

Search 215,058 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Amgen

Thousand Oaks, California, United States
Category Company
Founded 1980
Sector Life Science
Employees28,000
Revenue 33.4B USD (2024)
DESCRIPTION
Entrance to Amgen's corporate campus in Thousand Oaks, California.
Entrance to Amgen's corporate campus in Thousand Oaks, California.

Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.

DEAL STATS #
Overall 8 of 21
Sector: Life Science M&A 8 of 20
Type: Add-on Acquisition M&A Deals 8 of 20
State: Massachusetts M&A 3 of 3
Country: United States M&A 8 of 16
Year: 2011 M&A 1 of 2
Size (of disclosed) 10 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-06-06 Alantos Pharmaceuticals Holding

Cambridge, Massachusetts, United States

Alantos Pharmaceuticals is a chemistry-driven biopharmaceutical company with a proprietary pipeline of small molecule drugs focused in the area of type II diabetes and osteoarthritis / inflammation. With locations in Cambridge, Massachusetts and Heidelberg, Germany, Alantos Pharmaceuticals employs 45 people.

Buy $300M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-04-08 Bergamo

Sao Paulo, Brazil

Bergamo is a supplier of medicines to the hospital sector in Brazil with capabilities in oncology medicines and has manufacturing facilities in Sao Paulo state.

Buy $215M
Mergr

Solution for

Product

Company

Legal